UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000018626
Receipt number R000021554
Scientific Title Treatment for Adductor Spasmodic Dysphonia by Type 2 Thyroplasty using Titanium Bridges
Date of disclosure of the study information 2015/08/10
Last modified on 2017/08/16 08:58:49

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Treatment for Adductor Spasmodic Dysphonia by Type 2 Thyroplasty using Titanium Bridges

Acronym

Treatment for Adductor Spasmodic Dysphonia by Type 2 Thyroplasty using Titanium Bridges

Scientific Title

Treatment for Adductor Spasmodic Dysphonia by Type 2 Thyroplasty using Titanium Bridges

Scientific Title:Acronym

Treatment for Adductor Spasmodic Dysphonia by Type 2 Thyroplasty using Titanium Bridges

Region

Japan


Condition

Condition

Adductor Spasmodic Dysphonia

Classification by specialty

Oto-rhino-laryngology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate the efficacy and safety of type 2 thyroplasty using titanium bridges for adductor spasmodic dysphonia

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Explanatory

Developmental phase

Phase II,III


Assessment

Primary outcomes

Change from baseline in VHI-10 scores at 13 weeks after surgery

Key secondary outcomes

1. Changes in VHI-10 scores before and after surgery
2. Changes in VHI scores before and after surgery
3. Changes in VHI subscale scores in the functional (F), (P), and (E)
4. Changes in phonatory function test results before and after surgery
5. Changes in acoustic analysis results
6. Frequency of adverse events and device defects


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Device,equipment

Interventions/Control_1

Type 2 Thyroplasty using Titanium Bridges

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit

80 years-old >=

Gender

Male and Female

Key inclusion criteria

1. Diagnosis of adductor spasmodic dysphonia by a board certified otorhinolaryngologist certified by the Oto-Rhino-Laryngological Society of Japan, Inc.
2. At least 1 year experience of subjective or objective labored speech production, or pauses on certain sounds, due to adductor spasmodic dysphonia
3. A total score of 20 or more on the Voice Handicap Index-10 (VHI-10)
4. Non-responders to voice therapy performed before informed consent
5. 18 through 80 years of age inclusive at the time of informed consent
6. Written informed consent to participate in this study, provided by patients or their legally acceptable representatives

Key exclusion criteria

1. Dysphagia, laryngeal paralysis, or any structural disorder in the vocal cord
2. Previous surgery for adductor spasmodic dysphonia
3. Local injection of botulinum toxin type A into the intralaryngeal muscles within 6 months before informed consent
4. Serious concomitant diseases
5. Surgery with general anesthesia scheduled during the study period or surgery performed within the past 4 weeks
6. Participation in any other study using any other intervention within 12 weeks before informed consent, or planned participation in such a study during the study period after enrollment in this study
7. Psychiatric disorder requiring treatment, or mental or intellectual disability that may affect the conduct of the study
8. A history of alcoholism or drug abuse
9. A history of hypersensitivity to pure titanium
10. Women who are pregnant or planning to become pregnant during the study period
11. Patients deemed ineligible for this study by the investigator for any other reason

Target sample size

20


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Tetsuji Sanuki

Organization

Kumamoto University Hospital

Division name

Department of Otolaryngology-Head and Neck Surgery

Zip code


Address

1-1-1 Honjo Chuo-ku Kumamoto 860-8556 Japan

TEL

+81-96-373-5255

Email

otostl@gmail.com


Public contact

Name of contact person

1st name
Middle name
Last name Tetsuji Sanuki

Organization

Department of Otolaryngology-Head and Neck Surgery,Kumamoto University Hospital

Division name

Office for TS-001 Clinical Trial

Zip code


Address

1-1-1 Honjo Chuo-ku Kumamoto 860-8556 Japan

TEL

+81-96-373-5180

Homepage URL


Email

larynx@kumamoto-u.ac.jp


Sponsor or person

Institute

Kumamoto University

Institute

Department

Personal name



Funding Source

Organization

Intractable Disease Research/Japan Agency for Medical Research and Development

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor

Hokkaido University Hospital
Yokohama City University Hospital
Kyoto University Hospital

Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW

27-70/2015-03


Institutions

Institutions

国立大学法人熊本大学医学部附属病院(熊本県)/Kumamoto University Hospital,Kumamoto
国立大学法人北海道大学病院(北海道)/Hokkaido University Hospital,Hokkaido
公立大学法人横浜市立大学附属病院(神奈川県)/Yokohama City University,Kanagawa
国立大学法人京都大学医学部附属病院(京都府)/Kyoto University Hospital,Kyoto


Other administrative information

Date of disclosure of the study information

2015 Year 08 Month 10 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2015 Year 07 Month 27 Day

Date of IRB


Anticipated trial start date

2015 Year 08 Month 10 Day

Last follow-up date

2017 Year 03 Month 29 Day

Date of closure to data entry


Date trial data considered complete

2017 Year 05 Month 25 Day

Date analysis concluded

2017 Year 06 Month 21 Day


Other

Other related information



Management information

Registered date

2015 Year 08 Month 10 Day

Last modified on

2017 Year 08 Month 16 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000021554


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name